Vecima Announces Creation of Office of the CTO and Executive Leadership Changes
20.7.2020 18:50:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) announced today that it has made several organizational changes across the executive leadership team in alignment with the company’s growth and operational objectives.
Mr. Clay McCreery has been appointed Chief Operating Officer. Mr. McCreery previously served as Chief Revenue Officer for Vecima, as well as managing operations for the Content Delivery & Storage business unit. He joined Vecima through the acquisition of Concurrent Technology in 2017. Prior to joining Concurrent, Mr. McCreery was Senior Vice President of Sales of North America at ARRIS for 14 years. During his tenure there, he helped integrate several key acquisitions enabling ARRIS’ market share growth in Access Technologies, DOCSIS Services, and Content Delivery. “This is a pivotal time for the company and the industries we serve. I am thrilled to be part of an organization with the vision and determination to help our customers transition their networks for next-generation services,” said Mr. McCreery.
Mr. Colin Howlett has been appointed Chief Technology Officer and will lead the newly created Office of the CTO. Mr. Howlett previously served as Vice President of Architecture at Vecima, and his tenure with the company spans 23 years, leading engineering and architecture teams. His technical expertise spans a wide breadth, including wireless, wireline, RF, and software engineering. “Throughout my previous roles at Vecima, the aspect I’ve enjoyed most is partnering with the customers we serve to develop unique and compelling solutions to their technical challenges,” said Mr. Howlett. “I look forward to leading a team of world-class technology experts and industry thought leaders as we expand our reach.”
Mr. Kyle Goodwin has been promoted to SVP & General Manager of the Content Delivery & Storage business unit. Mr. Goodwin previously led Concurrent Technology’s research and development portfolio of products through a time of transition in the service provider industry. Prior to joining Concurrent, he spent time in the telecommunications, financial technology, and insurance industries with Motorola, PrimeRevenue, S1 Corporation, and Aflac. Mr. Goodwin is also a Steering Board Member of the DVB Project, an industry-led consortium defining the global standard for digital television.
Mr. Ryan Nicometo has been promoted to SVP & General Manager of the Video & Broadband Solutions business unit. Mr. Nicometo, who also joined Vecima from the acquisition of Concurrent Technology, brings 21 years of experience in the service provider space to his role. Prior to joining Concurrent, he held leadership roles at ARRIS Group, CCI Systems, and Motorola. While at Motorola and ARRIS, he helped integrate technology and talent from several acquisitions across roles in sales and product management.
Mr. Goodwin and Mr. Nicometo will report to Mr. McCreery in their new roles with the company.
“Both Ryan and Kyle have been key members of the management team and have been significant contributors in the success of the company over the last several years,” said Mr. McCreery.
“I am very excited to have Clay, Colin, Kyle, and Ryan take on expanded roles within the Vecima leadership team as we continue to execute on our strategy to serve our global service provider and broadcast customers with a powerful suite of products and technologies that fuel a more connected world,” said Mr. Sumit Kumar, President and Chief Executive Officer of Vecima. “Vecima is positioned for growth and investing in the futures of the industries we serve.”
About Vecima
Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high-capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005209/en/
Contact information
Vecima Networks
Investor Relations – 250-881-1982
invest@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom